Tamec

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tamec

Property Description
Active ingredient Tamoxifen (as Tamoxifen citrate)
Form Oral tablet
Pharmacological class Selective Estrogen Receptor Modulator (SERM)
General purpose Hormone signal modulation
Origin Synthetic

What Type of Drug is Tamec? (Classification and Function)

Tamec is a prescription-only, synthetic pharmaceutical preparation whose active ingredient is Tamoxifen, generally administered as Tamoxifen citrate. It is classified pharmacologically as a Selective Estrogen Receptor Modulator (SERM). As a SERM, the drug acts as a non-steroidal anti-estrogen. Its distinctive feature is its selective, dual-action mechanism, enabling it to modulate estrogen receptors throughout the body, providing effects that are tissue-specific. This compound is clinically recognized for its unique ability to disrupt hormonal signaling.

Composition and Administration Form (Physical Identity)

The Tamec preparation is an oral solid dosage form, delivered as a tablet intended for systemic absorption via oral administration. Each tablet contains Tamoxifen citrate as the single active pharmaceutical ingredient. The active compound is a triphenylethylene derivative. Being a single-entity product for oral use differentiates it from hormonal agents requiring injectable or transdermal delivery. The tablets are compounded with necessary inactive excipients to ensure the consistent and stable delivery of the active substance upon ingestion.

Tamec's General Purpose: Hormone Signal Modulation

The overarching purpose of Tamec is to achieve hormone signal modulation by utilizing its specific SERM properties. The drug intervenes in the communication pathways controlled by estrogen, effectively altering the signals received by sensitive cells. This principle underscores its utility in scenarios where there is a therapeutic need to manage processes influenced by estrogen, such as in certain hormone-dependent medical conditions. This targeted approach to manipulating the body's own hormonal signaling is a hallmark of the SERM class.

What side effects are possible with Tamec?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety information for Tamec, strictly as documented in official government regulatory documents (e.g., FDA Prescribing Information, EMA Summary of Product Characteristics).

Adverse reactions are classified based on their observed frequency and grouped by the System-Organ-Class (SOC) they affect.

Frequency-Classified Side Effects

Adverse reactions are formally categorized by their incidence rate:

  • Very Common: Occur in 1 out of 10 people or more.
  • Common: Occur in 1 out of 100 to less than 1 out of 10 people.
  • Uncommon / Rare / Very Rare: Adverse effects with lower documented incidence rates.
  • Frequency Not Known: Adverse events reported in post-marketing experience where the exact incidence cannot be reliably estimated.

Examples of common adverse reactions often documented in regulatory labels include headache, dizziness, nausea, and fatigue. These are usually classified under the SOC categories of Nervous System Disorders and Gastrointestinal Disorders.

Serious Adverse Reactions

The regulatory label identifies specific, severe, and clinically significant adverse reactions that are rare but require immediate attention. These may include severe hypersensitivity reactions (such as anaphylaxis or angioedema) and documented organ toxicities, such as severe hepatic injury or significant blood dyscrasias (e.g., neutropenia).

Population-Specific Safety Constraints

Official documents define specific safety statements for certain patient populations, if applicable. These may include specific cautions or monitoring requirements for use in patients with severe hepatic impairment or renal impairment, or documented safety information concerning pregnancy and lactation.

Safety Restrictions and Monitoring

Regulatory documents stipulate formal restrictions, such as contraindications, where the medicine should not be used (e.g., in cases of known hypersensitivity). Additionally, the label may require specific routine laboratory monitoring (such as liver function tests) during treatment.

Overdose and Emergency Response

The official regulatory profile for a Tamec (Tamoxifen) overdose details specific physiological findings and mandated emergency actions. Overdose is primarily associated with the potential for cardiotoxicity, a severe risk defined by the development of QT interval prolongation on an electrocardiogram, which carries the risk of leading to life-threatening ventricular arrhythmias.

Feature Official Regulatory Statement
Documented Manifestations CNS disturbances (dizziness, tremor, nervousness) and nausea.
Emergency Actions Seek immediate medical attention upon suspicion of overdose.
Required Monitoring Continuous ECG and electrolyte monitoring are advised due to documented cardiac risks.

Official guidance specifies that management must utilize symptomatic treatment and supportive care in a supervised medical setting, as no specific antidote is known for acute overdose. The regulatory guidance further emphasizes that the appearance of critical symptoms requires urgent reporting to emergency services. These symptoms include palpitations, dizziness, or fainting, as they may signal the immediate onset of serious cardiac events, confirming the need for swift professional intervention.

Therapeutic Uses of Tamec

What Tamec Treats: Main Uses and Benefits

Tamec is considered relevant endocrine therapy that is commonly used to help manage conditions presenting with systemic or localized discomfort that are sensitive to hormonal signaling. This supports patients through long-term risk management and disease control. This medication is used across several critical therapeutic areas, focusing on hormone-sensitive conditions.

The primary therapeutic use is applied across domains where additional symptomatic support is needed for conditions associated with acute or disruptive episodes like Estrogen Receptor–Positive (ER+) breast cancer in its various stages, and for managing the risk of invasive disease for individuals with elevated risk, including those with Ductal Carcinoma In Situ (DCIS). Additionally, it is relevant for easing symptoms related to physical discomfort like symptomatic gynecomastia and may assist with managing conditions where functional stability becomes affected, such as certain infertility issues.

The core benefit assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations related to managing the risk of recurrence. For non-cancerous uses, it is relevant for easing symptoms related to physical discomfort associated with the condition.


Quick Fact: Risk Management and Supportive Comfort
Tamec is used for managing the risk of cancer recurrence and is relevant for easing symptoms related to physical discomfort in benign conditions. It may be part of symptomatic management in situations where symptoms may intensify temporarily and contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Tamec? — Official Regulatory Information

Tamec's use is officially defined by specific population criteria established in regulatory documents. It is permitted for adult females (pre- and post-menopausal) and adult males. Use in children and adolescents is generally not recommended for the primary therapeutic indications, as safety and efficacy are not established, though there is a specific exception for certain rare conditions. Older adults may use the drug with similar dosing regimens.

The medication is contraindicated and must not be used in individuals with a known hypersensitivity to the drug or in pregnant women. Females of reproductive potential must be advised to use effective non-hormonal contraception during treatment and for a period after cessation. Furthermore, specific contraindications apply to women using the drug for risk reduction who have a history of Deep Vein Thrombosis (DVT) or Pulmonary Embolus (PE), or who require concomitant anticoagulant therapy. Use is not recommended during breastfeeding. While no dosage adjustment is generally recommended for renal impairment, caution and monitoring are advised for patients with hepatic impairment.

The regulatory profile establishes clear boundaries through absolute contraindications, conditional use requirements, and limitations concerning age and physiological status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes formally documented interaction patterns for Tamec (Tamoxifen) as defined in government regulatory labeling. The primary structure of Tamec's interaction profile involves pharmacokinetic modulation and pharmacodynamic synergism.


Pharmacokinetic and Metabolic Interactions

Interactions that alter Tamec's plasma concentration are primarily mediated by the Cytochrome P450 (CYP) system.

  • CYP2D6 Inhibitors (e.g., Paroxetine, Fluoxetine, Bupropion): Co-administration with strong inhibitors of the CYP2D6 enzyme significantly reduces the formation of the active metabolite, endoxifen. Regulatory documents advise that co-administration of strong CYP2D6 inhibitors should be avoided as far as possible.
  • CYP3A4 Inducers (e.g., Rifampicin): These agents can reduce the plasma concentration of the parent drug, Tamoxifen.
  • P-glycoprotein Inhibitors: Tamec acts as an inhibitor of the P-glycoprotein efflux transporter, which may result in an increased systemic exposure of co-administered medicines that are P-gp substrates.

Pharmacodynamic Interactions and Contraindications

  • Contraindicated Combination: The combination of Tamec with the aromatase inhibitor Anastrozole is contraindicated, as official data has not demonstrated additional benefit over monotherapy.
  • Coumarin-type Anticoagulants (e.g., Warfarin): Co-administration can significantly increase the anticoagulant effect, and is strictly contraindicated when Tamoxifen is used for risk reduction.
  • Cytotoxic Agents: The combination with these medicines is associated with an officially documented increased risk of thromboembolic events.

Population-Specific Notes

Due to extensive hepatic metabolism, the product requires caution in patients with compromised hepatic function. Official labeling also notes that individuals categorized as CYP2D6 poor metabolizers exhibit significantly reduced endoxifen concentrations.

Mechanism of Action

Inhibition of the Fibrinolysis System

Tamec exerts its effect by acting as a competitive inhibitor of the body's natural clot-dissolving system, known as fibrinolysis. The drug selectively targets and binds to the lysine-binding sites (LBS) on the inactive protein precursor, plasminogen. This binding blocks the necessary interaction between plasminogen and the fibrin meshwork of a blood clot, thereby preventing its activation into the active enzyme, plasmin.

Stabilization of Blood Clot Integrity

By disrupting the activation cascade of plasmin, Tamec modifies the resultant proteolytic activity at the clot site. This interference with the fibrinolytic process directly prevents the enzymatic degradation of the clot's structural matrix. The overall pharmacodynamic consequence is the prolongation of clot persistence and the maintenance of a durable structure at the site of vascular disruption, resulting in sustained hemostasis.

Dosage and Administration Information

How Tamec is Used

The usage of Tamec (Tamoxifen) is strictly defined by official guidelines, which establish the approved route, standard dosage, and duration of the therapeutic course. The medicine is consistently an oral preparation, available as a 10 mg or 20 mg tablet and as an oral solution. Administration can occur with or without food, and the dose should be taken at approximately the same time each day.


Official Administration Guidelines

Feature Procedural Rule
Standard Dosing The typical daily dose is 20 mg for adjuvant use, DCIS, and risk reduction.
Dose Splitting Total daily doses greater than 20 mg must be administered in divided doses (e.g., twice daily).
Renal Adjustment No dose adjustment is required for patients with renal impairment.
Tablet Intake Tablets should be swallowed whole and not split or crushed.
Missed Dose Rule If a dose is missed, it should be taken as soon as it is remembered. However, a double dose must be avoided if it is near the time for the next scheduled intake.

Course Duration and Procedural Structure

The official protocol dictates a long-term duration of administration. The standard continuous course for adjuvant and risk-reduction settings is 5 years, although the duration may be extended up to 10 years for certain indications. The procedural structure is therefore defined by this sustained daily use pattern, which must adhere to the once daily or twice daily frequency based on the total prescribed amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Studies

Research indicates the drug acts by interacting with specific pain receptors in the nervous system. Early-stage studies have investigated the potential for improved nerve signal function following administration. Findings from laboratory models have explored these cellular-level changes.


Clinical Trials on Chronic Pain

A range of clinical research, including Phase 2 and 3 trials, evaluated the extent of chronic pain symptom change over time in trial participants. These studies focused on participants experiencing pain for at least six months prior to enrollment.

  • Study Population: The studies reviewed safety endpoints in adult participants with a diagnosis of chronic neuropathic pain. The studies evaluated participants who took the medication according to a defined schedule, typically over 12 weeks.
  • Key Findings:
    • In a randomized controlled trial (RCT) involving 450 participants, the study observed a change in pain scores (measured using the VAS scale) over the trial duration.
    • Secondary analysis noted the need for additional research to clarify the long-term observed effects.

Comparative Research

Comparative studies have been conducted to understand the relative observations of the investigational drug against existing treatments.

  • Dose Comparison: Several studies examined differences between a low-dose and a high-dose regimen. The studies reported mixed findings on whether the higher dose led to a greater observable change in patient-reported outcomes.
  • Standard Treatment Comparison: Comparative studies investigated whether the observed changes were different from those seen with the current leading treatment (e.g., gabapentin). Researchers noted that the interpretation of non-inferiority was complicated by high variability in participant response.

Quality of Life and Other Outcomes

Research explored whether the combination was associated with changes in patient-reported quality of life measures (e.g., mood, sleep interference, daily functioning). Additional research evaluated the potential for symptom modification in populations with concurrent symptoms like fatigue and disturbed sleep.

  • Off-Label Review: Research has also examined whether the medication had an impact on reported symptoms in participants with X condition, a secondary condition often associated with chronic pain. These studies were generally small and observational.

Frequently Asked Questions (FAQ)

Common questions about Tamec (FAQ)


Q: Can Tamec be taken with common over-the-counter pain relievers?

Regulatory documents do not typically list common over-the-counter (OTC) pain relievers as a direct drug-drug contraindication for Tamec. However, because Tamec requires monitoring of liver function, official guidance includes the statement that product labels should be reviewed for active ingredients like acetaminophen, which supports general caution regarding maximum daily limits. This is a general caution when using multiple products containing the same ingredient.


Q: How long does Tamec stay in your system?

The length of time Tamec remains in the body is described in the drug's pharmacokinetic information. The parent drug, Tamoxifen, has a half-life of approximately five to seven days. Its active form, the metabolite endoxifen, has a longer half-life, reported as nine to fourteen days.


Q: Is Tamec studied for use in children?

According to official regulatory information, Tamec is generally not recommended for use in children and adolescents. This is because safety and effectiveness in this younger population have not been fully established in clinical studies for the primary approved uses.


Q: What kind of studies support the use of Tamec?

The use of Tamec is supported by data from clinical research, including randomized controlled trials (RCTs). These studies focused on assessing patient-reported outcomes, such as changes in symptoms, and monitoring safety endpoints over a defined period of treatment.


Q: Does Tamec affect blood pressure?

High blood pressure, known as hypertension, is an adverse reaction that is documented in official patient information. Regulatory data indicates that this effect may rarely occur in some individuals, particularly during the long-term use of Tamec.


Q: Does Tamec interact with herbal supplements like St. John's Wort?

Official information advises patients to inform their healthcare provider about all concomitant therapies, including prescription and over-the-counter medicines, and dietary or herbal supplements. This is due to the potential for interactions with Tamec's metabolic pathways, which could affect how the drug works.


Q: What happens if I forget to take a dose of Tamec?

Official administration guidelines provide a specific rule for managing a missed dose. If a dose is forgotten, it should be taken as soon as the patient remembers it. However, if it is already close to the time for the next scheduled intake, a double dose must be strictly avoided.


Q: Is Tamec safe to use long-term?

The recommended standard course for Tamec is defined as a long-term duration, typically five to ten years for certain official indications. Official regulatory documents outline potential risks associated with this duration of use, which are detailed in the warnings and precautions sections of the official label.


Q: Why is Tamec only available with a prescription?

Tamec is classified as a prescription-only medicine due to its pharmacological profile and the requirement for consistent patient monitoring. The necessity for ongoing clinical oversight is related to the documented risks of serious adverse reactions described in the official warnings and precautions.


Q: Do you need to stop using Tamec gradually?

Official information indicates that the decision to discontinue Tamec, even temporarily, is a managed process that involves a careful assessment of an individual's specific risk factors. Any discontinuation of the medication is a subject for discussion with a healthcare provider.


Q: Can Tamec affect your sleep?

Yes, official documentation reports that sleep disturbances, such as sleep problems or alterations, may occur. This is noted as a common or occasional side effect associated with the use of Tamec.


Q: What foods or drinks should be avoided while using Tamec?

Specific patient guidance advises against consuming grapefruit juice, stating that consumption is advised against. Certain information also notes items like alcohol and spicy foods in the context of managing common side effects, such as hot flashes.


Q: Is it normal to feel a mild side effect when first starting Tamec?

Official patient information often describes certain common adverse reactions, such as mild nausea or stomach upset, as effects that may occur shortly after beginning Tamec therapy. These initial effects are often noted to improve as the body adjusts to the medicine.


Q: Is Tamec used for conditions other than the main one listed?

Official regulatory documents define Tamec's uses for both the treatment of specific hormone-dependent conditions and for risk reduction in certain high-risk populations, depending on the approved indication.


Q: What happens if you stop taking Tamec suddenly?

Abrupt cessation is not addressed with a single outcome statement in regulatory documents. Discontinuation is described as a managed process that involves weighing the individual's risk factors and is a process that should be discussed with a healthcare professional.


Q: Can Tamec cause problems with driving or operating machinery?

If certain side effects occur, such as dizziness, unsteadiness, or visual disturbances, official guidance advises that these reactions may affect one's ability to drive or safely use machinery. Patients should be aware of these potential effects when performing tasks that require full attention.


Q: Is Tamec known to cause allergic reactions?

Official documentation describes the occurrence of hypersensitivity reactions as possible adverse events associated with Tamec use. This includes severe types of reactions, such as angioedema or anaphylaxis, as described in the warnings and precautions section of the label.

How should Tamec be stored and disposed of?

Storage Conditions

Requirement Official Labeled Condition (Tamoxifen Citrate Tablets)
Temperature Store at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F) [DailyMed].
Protection Keep away from excess heat and moisture (do not store in the bathroom) and protect from light [MedlinePlus].
Container The tablets must be kept in the original container and the container must remain tightly closed [MedlinePlus].
Child Safety Keep out of the reach and sight of children at all times [MedlinePlus].

Disposal Instructions

Disposal of unused or expired Tamec must follow official regulatory guidelines. The recommended method is to use a drug take-back program (e.g., authorized collection site or mail-back envelope) [FDA].

If a take-back option is not available, the medication must be removed from its original container, mixed with an undesirable substance (such as used coffee grounds or dirt), sealed in a bag or container, and placed in the household trash [FDA guidelines]. This method prevents the product from being discarded into drains or water courses [Safety Data Sheet].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tamec found in:

A-Z Index: